Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO – Get Free Report) shot up 15.2% during trading on Friday . The company traded as high as $4.10 and last traded at $3.79. Approximately 396,905 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 2,798,922 shares. The stock had previously closed at $3.29.
Entero Therapeutics Stock Performance
The firm has a market capitalization of $6.02 million, a PE ratio of -2.24 and a beta of 1.19. The stock’s 50 day simple moving average is $4.12 and its two-hundred day simple moving average is $3.37.
Hedge Funds Weigh In On Entero Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in Entero Therapeutics during the third quarter worth $59,000. GSA Capital Partners LLP purchased a new stake in Entero Therapeutics in the 2nd quarter valued at $65,000. Persistent Asset Partners Ltd acquired a new stake in shares of Entero Therapeutics in the 2nd quarter worth $198,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Entero Therapeutics in the 2nd quarter worth $3,642,000. Hedge funds and other institutional investors own 12.30% of the company’s stock.
About Entero Therapeutics
Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.
Entero’s pipeline features multiple lead candidates in varying stages of clinical development.
Further Reading
- Five stocks we like better than Entero Therapeutics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
